Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3 results about "Monoamine transporter" patented technology

Monoamine transporters (MATs) are protein structures that function as integral plasma-membrane transporters to regulate concentrations of extracellular monoamine neurotransmitters. Three major classes of MATs (SERT, DAT, NET) are responsible for the reuptake of their associated amine neurotransmitters (serotonin, dopamine, norepinephrine). MATs are located just outside the synaptic cleft (peri-synaptically), transporting monoamine transmitter overflow from the synaptic cleft back to the cytoplasm of the pre-synaptic neuron. MAT regulation generally occurs through phosphorylation and posttranslational modification. Due to their significance in neuronal signaling, MATs are commonly associated with drugs used to treat mental disorders as well as recreational drugs, a line that can become quite blurred in many cases. Compounds targeting MATs range from medications such as the wide variety of tricyclic antidepressants, selective serotonin reuptake inhibitors such as fluoxetine (Prozac) to stimulant medications such as methylphenidate (Ritalin) and amphetamine in its many forms (Adderall, Dexedrine) and derivatives methamphetamine (Desoxyn) and lisdexamfetamine (Vyvanse). Furthermore, drugs such as MDMA ("ecstasy", "molly") and natural alkaloids such as cocaine exert their effects in part by their interaction with MATs, by blocking the transporters from mopping up dopamine, serotonin, and other neurotransmitters from the synapse.

Aryl-containing amine compound, preparation method therefor and use thereof

PendingUS20260174739A1Organic active ingredientsNervous disorderNR1 NMDA receptorDisease
Disclosed in the present invention are an aryl-containing amine compound, a preparation method therefor and a use thereof. The aryl-containing amine compound is represented by formula (I), and has the function of regulating the activity of an NMDA receptor and / or a monoamine transporter and / or a sigma receptor. Thus, the compound can be used for preparing drugs for treating and / or preventing diseases associated with an NMDA receptor and / or a monoamine transporter and / or a sigma receptor, especially central nervous system diseases.
Owner:SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES +2

Aryl group-containing amine compounds, their preparation and use

PendingJP2025538201ANervous disorderOrganic chemistryNR1 NMDA receptorDisease
The present invention discloses an aryl group-containing amine compound, its preparation method, and use. The aryl group-containing amine compound is represented by formula (I), and has the function of regulating NMDA receptor and / or monoamine transporter and / or sigma receptor activity, and can be used to prepare a medicament for treating and / or preventing diseases associated with NMDA receptors and / or monoamine transporters and / or sigma receptors, particularly central nervous system diseases. JPEG2025538201000350.jpg4951
Owner:SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES +2

Diazabicyclic modulators of monoamine transporters

PCT designated stageWO2026033049A1Nervous disorderOrganic chemistryAzabicyclaneNeuro-degenerative disease
Disclosed are compounds of the formulae (II) and (III), and pharmaceutically acceptable salts thereof: (II) (III) wherein * represents the relative cis- or trans- conformations in formulae (II) and (III) respectively and R1, R2, each R3, each R4, n and m are as defined herein. The compounds are modulators of norepinephrine transporters (NET), dopamine transporters (DAT), serotonin transporters (SERT), sigma-1 receptor (σ1R), muscarinic M1 receptors and / or muscarinic M2 receptors and are expected to be useful in the treatment of pain, neuropsychiatric or neurodegenerative diseases, sleep disorders, as a sedative or as an anaesthetic.
Owner:UNIVERSITY OF BERN